530 related articles for article (PubMed ID: 32633471)
1. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
Kang KW; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
Cancer Med; 2020 Sep; 9(17):6102-6110. PubMed ID: 32633471
[TBL] [Abstract][Full Text] [Related]
2. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
Brito M; Esteves S; André R; Isidoro M; Moreira A
Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
[TBL] [Abstract][Full Text] [Related]
3. Primary prophylaxis with pegfilgrastim during the first cycle of R-CHOP to avoid reduction of dose intensity in elderly patients.
Ise M; Matsuda K; Shimura A; Masamoto Y; Kurokawa M
Int J Hematol; 2021 Jun; 113(6):823-831. PubMed ID: 33738702
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
5. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
[TBL] [Abstract][Full Text] [Related]
6. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
7. A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09.
Lee KH; Kim JY; Lee MH; Han HS; Lim JH; Park KU; Park IH; Cho EK; Yoon SY; Kim JH; Choi IS; Park JH; Choi YJ; Kim HJ; Jung KH; Kim SY; Oh DY; Im SA
Support Care Cancer; 2016 Apr; 24(4):1709-17. PubMed ID: 26423618
[TBL] [Abstract][Full Text] [Related]
8. Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy.
Wang XJ; Tang T; Farid M; Quek R; Tao M; Lim ST; Wee HL; Chan A
PLoS One; 2016; 11(2):e0148901. PubMed ID: 26871584
[TBL] [Abstract][Full Text] [Related]
9. Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma.
Kim DY; Nam J; Chung JS; Jeon BE; Lee JH; Jo JC; Kim SW; Shin HJ
Cancer Res Treat; 2022 Oct; 54(4):1256-1267. PubMed ID: 34990523
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
Kahan Z; Grecea D; Smakal M; Tjulandin S; Bondarenko I; Perjesi L; Illes A; Horvat-Karajz K; Aradi I
BMC Cancer; 2019 Feb; 19(1):122. PubMed ID: 30727980
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy].
Kataoka T; Sakurashita H; Taogoshi T; Nishigakiuchi R; Murase T; Izumitani S; Saeki Y; Matsuo H
Yakugaku Zasshi; 2019; 139(4):629-633. PubMed ID: 30930398
[TBL] [Abstract][Full Text] [Related]
12. A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.
Cobb PW; Moon YW; Mezei K; Láng I; Bhat G; Chawla S; Hasal SJ; Schwartzberg LS
Cancer Med; 2020 Sep; 9(17):6234-6243. PubMed ID: 32687266
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
Yokoyama M; Kusano Y; Nishihara A; Inoue N; Nishimura N; Mishima Y; Terui Y; Nukada T; Nomura T; Hatake K
Support Care Cancer; 2020 Feb; 28(2):571-579. PubMed ID: 31093770
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study.
Wang CY; Vouri SM; Park H; Heldermon CD; Brown JD
J Manag Care Spec Pharm; 2023 Feb; 29(2):119-127. PubMed ID: 36705287
[No Abstract] [Full Text] [Related]
15. Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study.
Jeong SH; Kim SJ; Yoon DH; Park Y; Kang HJ; Koh Y; Lee GW; Lee WS; Yang DH; Do YR; Kim MK; Yoo KH; Choi YS; Yun HJ; Yi JH; Jo JC; Eom HS; Kwak JY; Shin HJ; Park BB; Hyun SY; Yi SY; Kwon JH; Oh SY; Kim HJ; Sohn BS; Won JH; Kim SH; Lee HS; Suh C; Kim WS
Cancer Res Treat; 2022 Oct; 54(4):1268-1277. PubMed ID: 34990525
[TBL] [Abstract][Full Text] [Related]
16. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
Blackwell K; Donskih R; Jones CM; Nixon A; Vidal MJ; Nakov R; Singh P; Schaffar G; Gascón P; Harbeck N
Oncologist; 2016 Jul; 21(7):789-94. PubMed ID: 27091420
[TBL] [Abstract][Full Text] [Related]
17. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
Blackwell K; Gascon P; Jones CM; Nixon A; Krendyukov A; Nakov R; Li Y; Harbeck N
Ann Oncol; 2017 Sep; 28(9):2272-2277. PubMed ID: 28637287
[TBL] [Abstract][Full Text] [Related]
18. Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.
Botteri E; Krendyukov A; Curigliano G
Eur J Cancer; 2018 Jan; 89():49-55. PubMed ID: 29227817
[TBL] [Abstract][Full Text] [Related]
19. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.
McBride A; Krendyukov A; Mathieson N; Campbell K; Balu S; Natek M; MacDonald K; Abraham I
J Med Econ; 2020 Jan; 23(1):28-36. PubMed ID: 31433700
[No Abstract] [Full Text] [Related]
20. Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy.
McBride A; Alrawashdh N; Bartels T; Moore L; Persky D; Abraham I
Future Oncol; 2021 Sep; 17(26):3485-3497. PubMed ID: 34241542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]